Science
Weight loss outperformed placebo, but HbA1c fell by only 0.65 percentage points Rather than becoming a blockbuster on its own, the drug may be limited to combination and maintenance therapy

Petrelintide, an amylin analog being developed by Roche and Zealand Pharma, produced meaningful weight loss but showed limited glucose-lowering effects, prompting analysts to say its use may be confined to combination and maintenance therapy rather than first-line monotherapy.
Zealand Pharma announced Oct. 7 topline results from the phase 2 ZUPREME-2 trial, which enrolled 220 adults with type 2 diabetes who were overweight or had obesity. According to a report by Biobook on Oct. 12, in the trial, which tested once-weekly subcutaneous administration, petrelintide produced mean weight loss of up to 9.2% from baseline at week 28. That was well above the 2.0% in the placebo group.
Because people with diabetes tend to lose less weight than people without diabetes, in part because of insulin resistance, the result approaches the 9.8% weight loss at week 28 in ZUPREME-1, a trial in people with obesity who did not have diabetes.
But the results were different for measures of glycemic control. At week 28, HbA1c fell by up to 0.65 percentage points in the petrelintide group. HbA1c rose by 0.23 percentage points in the placebo group, yielding a placebo-adjusted reduction of 0.61 to 0.88 percentage points, but the absolute reduction falls short of that seen with competing candidates.
Amylin receptor agonist eloralintide from Eli Lilly and amylin and GLP-1 combination drug CagriSema from Novo Nordisk have typically demonstrated HbA1c reductions of 1.3 to 2.1 percentage points. Analysts say the placebo-adjusted effect may appear exaggerated because HbA1c rose unusually in the placebo group, but the drug’s glucose-lowering mechanism alone may not justify monotherapy in people with obesity who need diabetes treatment.
Amylin is secreted alongside insulin by pancreatic beta cells, slows gastric emptying and acts on the central nervous system to promote satiety. Its appetite-suppressing and leptin-sensitizing mechanisms have been considered advantages over glucagon-like peptide-1 (GLP-1) drugs, potentially causing fewer gastrointestinal adverse effects such as vomiting and diarrhea and reducing muscle loss.
In this trial, treatment discontinuation because of gastrointestinal adverse events was 1.9% in the petrelintide group and 1.7% in the placebo group, indicating tolerability essentially on par with placebo. This distinguishes it from GLP-1 drugs, which have many early discontinuations because of nausea and other effects.
However, limited glucose-lowering ability despite good tolerability could narrow the drug’s prescribing range. Given that many people with obesity also have impaired glucose tolerance or type 2 diabetes, analysts say a treatment that cannot lower HbA1c by at least 1 percentage point is unlikely to displace GLP-1 drugs as a first-line option in the endocrinology market.
Roche paid $1.65 billion in upfront and milestone payments to license petrelintide last year. Analysts increasingly expect its market opportunity to be limited to long-term maintenance therapy after rapid weight loss or as an alternative for patients who do not respond to GLP-1 drugs, rather than the standalone blockbuster status anticipated at the time.
Ultimately, analysts say petrelintide’s commercial prospects will depend on the strength of its combination strategy, not monotherapy. Roche and Zealand Pharma launched a phase 3 registration program in September involving a total of 7,000 participants: ZUPREME-3, with 3,900 people with obesity who do not have diabetes; ZUPREME-4, with 600 people with obesity and type 2 diabetes; and ZUPREME-5, with 2,500 people with cardiovascular disease.
A phase 2 combination trial with Roche’s GLP-1 and GIP dual agonist enisefatide is also expected to get underway in earnest this year. Given the limitations of amylin monotherapy in achieving both weight loss and normalized blood glucose, petrelintide’s practical value will ultimately be judged by whether it can improve GLP-1 tolerability and deliver synergy as part of a combination drug.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”